Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

Ovid Technologies (Wolters Kluwer Health) - Tập 124 Số 14 - Trang 1573-1579 - 2011
Elise S Eerenberg1, Pieter W. Kamphuisen1, Meertien K. Sijpkens1, Joost C.M. Meijers1, Harry R. Büller1, Marcel Levi1
1From the Departments of Vascular Medicine (E.S.E., P.W.K., M.K.S., J.C.M., H.R.B., M.L.) and Experimental Vascular Medicine (J.C.M.), Academic Medical Center, Amsterdam, the Netherlands.

Tóm tắt

Background— Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs. Methods and Results— In a randomized, double-blind, placebo-controlled study, 12 healthy male volunteers received rivaroxaban 20 mg twice daily (n=6) or dabigatran 150 mg twice daily (n=6) for 2½ days, followed by either a single bolus of 50 IU/kg PCC (Cofact) or a similar volume of saline. After a washout period, this procedure was repeated with the other anticoagulant treatment. Rivaroxaban induced a significant prolongation of the prothrombin time (15.8±1.3 versus 12.3±0.7 seconds at baseline; P <0.001) that was immediately and completely reversed by PCC (12.8±1.0; P <0.001). The endogenous thrombin potential was inhibited by rivaroxaban (51±22%; baseline, 92±22%; P =0.002) and normalized with PCC (114±26%; P <0.001), whereas saline had no effect. Dabigatran increased the activated partial thromboplastin time, ecarin clotting time (ECT), and thrombin time. Administration of PCC did not restore these coagulation tests. Conclusion— Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study. Clinical Trial Registration— URL: http://www.trialregister.nl . Unique identifier: NTR2272.

Từ khóa


Tài liệu tham khảo

10.1378/chest.08-0670

10.1177/0091270006286904

10.2165/00003088-200847050-00001

10.1007/s00228-010-0889-z

10.1056/NEJMoa1007903

10.1016/j.thromres.2010.03.021

10.1056/NEJMoa0906598

European Medicines Agency (EMEA). CHMP assessment report for Xarelto (rivaroxaban). 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf. Accessed March 28 2011.

Health Canada. Note of decision for Xarelto. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2009_xarelto_119111-eng.php. 2008. Accessed March 28 2011.

European Medicines Agency (EMEA). CHMP assessment report for Pradaxa (dabigatran). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. 2008. Accessed March 28 2011.

Health Canada. Note of decision for Pradax. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2008_pradax_114887-eng.php. 2008. Accessed March 28 2011.

US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. 2010. Accessed March 28 2011.

10.1111/j.1538-7836.2009.03429.x

Pezborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (presented at the 21st International Congress on Thrombosis) [abstract]. Pathophysiol Haemost Thromb. 2010; 37: A10-OC251.

van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (presented at the 13th Congress of the European Hematology Association) [abstract]. Haematologica. 2008; 93: 148–0370.

10.1161/ATVBAHA.110.202978

10.1177/0091270005274550

10.1007/s00228-005-0043-5

10.1056/NEJMoa0905561

Sanquin. Cofact: summary of product characteristics. http://www.sanquin.nl/Sanquin-eng/sqn_Cofact_eng.nsf/All/F9B2/$FILE/M%201.3.1%20SPC%20ENG%202006-11-17.pdf. 2005. Accessed March 28 2011.

10.1111/j.1742-1241.2008.01859.x

10.1177/0091270007302952

10.1160/TH09-11-0758

10.1160/TH07-03-0183

10.1159/000071636

Van Ryn J, Dörr B, Kaspereit F, Krege W, Zeitler S, Pragst I. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits (presented at the 21st International Congress on Thrombosis) [abstract]. Pathophysiol Haemost Thromb. 2010; 37: A94–P486.

10.1160/TH03-09-0605

10.1161/01.cir.0000038501.87442.02

10.1111/j.1365-2141.2003.04811.x

10.1002/ajh.21046

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 124 Số 14

1573-1579

Thông tin tác giả